Articles tagged with Blood Diseases
Researchers developed synthetic platelet-like particles that can augment natural blood clotting, potentially reducing trauma-related bleeding deaths. The particles were tested in animal models and human blood, showing effectiveness in slowing bleeding without causing adverse effects.
Rice University researchers have discovered a biochemical link between blood clotting and the immune system, which could lead to new treatments for patients with inflammatory diseases. The study found that a protein involved in blood clotting also triggers the body's immune response.
Researchers propose a novel risk stratification model for bladder cancer patients treated with radical cystectomy, utilizing clinico-pathological and pre-operative hematological factors. The study found that low hemoglobin and high C-reacted protein levels are independent prognostic indicators for disease-specific survival.
Researchers examined current treatment standards for patients with clotting disorders, aiming to reduce toxicities and relapse rates. Maintaining hematocrit levels below 45% was associated with a lower risk of thrombosis compared to a more liberal approach.
Researchers at UW-Madison have identified a small DNA sequence, the +9.5 GATA2 switch site, that plays a crucial role in controlling GATA2 production and generating self-renewing blood stem cells.
A Finnish research team has uncovered the protein structure that regulates cell signalling and blood cell formation, shedding light on haematological disorders. The study provides new opportunities for disease-specific treatment and may lead to targeted therapeutics for common myeloproliferative diseases.
Researchers discovered that 40% of LGL patients have a STAT3 mutation, which may aid in diagnosing and treating the disease. The mutation is also associated with an increased risk of rheumatoid arthritis, opening new avenues for understanding its pathogenesis.
A small study of 25 patients with hereditary hemorrhagic telangiectasia found improved cardiac output and reduced duration and number of episodes of nose bleeds after receiving bevacizumab. The treatment also significantly improved quality of life, with moderate toxicity observed.
The National Institutes of Health has signed a research and development agreement with two non-profit organizations to develop potential clinical therapies for rare blood cancers. The collaboration aims to bridge the gap between basic research and human testing, with the goal of accelerating the delivery of improved therapies to patients.
Researchers found that N-acetylcysteine reduces the size and activity of von Willebrand factor multimers in human plasma and mice, offering a potential rapid treatment for patients with TTP. The study suggests that this approach could be effective in reducing complications associated with current treatments.
A study has revealed a relationship between blood cells and their stem cell 'parents', influencing gene expression and behavior. The discovery opens up new research avenues into diseases caused by stem cell disorders.
Researchers from Massachusetts General Hospital are leading teams to develop stem-cell-based models of cardiovascular and blood disorders. The NHLBI grants will support the development of regenerative therapies for heart failure and other disorders.
Researchers analyzed 17,398 patient records and found only 14 real disease associations with MGUS, not 61 as previously reported. This finding may reduce unnecessary testing and treatment for patients with MGUS.
A study found that miR-143 and miR-145 regulate the contractile nature of vascular smooth muscle cells, with their absence leading to increased tissue matrix production and signs of blood vessel disease. The findings suggest these microRNAs could serve as therapeutic targets for enhancing blood vessel repair.
Researchers identified a common genetic sequence alteration that enhances the likelihood of acquiring a mutation in a gene linked to certain blood diseases. Patients with myeloproliferative neoplasms have a higher risk of developing another JAK2 mutation due to inherited DNA sequence changes.
Researchers at Yale School of Medicine developed a man-made anti-clotting protein that prevents excessive clotting in patients with hereditary antithrombin deficiency. The treatment showed no adverse effects during treatment or seven days after treatment, indicating its potential to prevent complications linked to the condition.
The American Society of Hematology has launched an initiative to provide increased support for training programs in hematology-related disciplines. Three grant recipients will develop new curricula that integrate emerging technologies into traditional training programs, addressing the need for clinicians and clinical researchers with s...
International health experts call for urgent action from international development banks and pharmaceutical companies to address blood pressure-related diseases affecting developing countries. The authors argue that deaths from heart disease and stroke are largely avoidable but lack of effort has resulted in over 50 million deaths, wit...
The NHLBI-funded program aims to translate knowledge into clinical practice for treating heart, lung, and blood diseases. It focuses on repairing damaged heart muscle, reducing immune complications, and enhancing adult stem cell interactions.
Researchers have identified the Dido gene as a potential tumor suppressor involved in myeloproliferative diseases. The study found that 100% of patients with these diseases had Dido expression abnormalities, suggesting a link between the gene and the development of MDS/MPD.
A new diagnostic test is being developed to target a range of blood disorders by detecting a single point mutation in the JAK2 gene. The mutation was found in virtually all patients with polycythaemia vera, as well as half of those with essential thrombocythaemia and idiopathic myelofibrosis.
A French study found that intravenous immunoglobulin improved platelet counts in adults with AITP. The study also showed that oral steroids and placebo had similar efficacy rates. The researchers suggest judicious observation for patients without severe bleeding and recommend specific immune-based therapies.
Researchers found that half of patients admitted to hospital with life-threatening symptoms of heart failure had diastolic heart failure, a previously under-studied disorder. The study emphasizes the need for further research into treatment options for this common form of heart failure.
A Phase III study found significant improvements in overall survival, disease-free status, and complete remission rates for patients with aggressive non-Hodgkin's lymphoma treated with MabThera and CHOP chemotherapy. Survival at 1-year was 83% for the rituximab combination therapy group compared to 68% for those receiving CHOP alone.
Mayo Clinic researchers have developed a new antibody test to help diagnose autonomic disorders caused by the immune system. The test detects antibodies that bind to an important protein on autonomic nerve cells, helping physicians evaluate patients with autonomic failure.
A nationwide consortium of nine institutions aims to improve treatment outcomes for children with neuroblastoma by testing new therapies and sharing research information. The project has already shown promising results in improving disease-free survival rates and may lead to faster development of effective treatments.
A new study shows Bexxar produced tumor shrinkage in 97% of patients with advanced-stage, low-grade non-Hodgkins lymphoma. Most patients achieved complete remission, with no sign of cancer, and molecular remissions lasting up to three years.
A study using polymerase chain reaction detects MRD in long-term CML survivors, finding that approximately 25% of patients had evidence of disease at some time after transplant. The team aims to identify patients who appear cured but may still harbor disease and benefit from early therapeutic intervention.
Researchers at Johns Hopkins Medicine have identified a unique molecular defect responsible for polycythemia vera, a blood disorder that can be difficult to diagnose. The finding may lead to the development of a definitive test for the condition, which could potentially increase patient lifespan.
Researchers have developed a genetic test that can identify children with obsessive-compulsive disorder (OCD) and tic disorders associated with strep throat infections. The blood test detects the D8/17 genetic marker in 85% of children with strep-associated OCD and tics, and 89% of those with Sydenham's chorea.
Researchers developed a new technique to measure electrical impulses in the trigeminal nerve, a major nerve in the jaw. The technique accurately measured the nerve's electrical impulses, helping researchers determine normal levels for electrical activity in these branches.